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CASE REPORT Open Access
MDA-5 associated rapidly progressive
interstitial lung disease with recurrent
Pneumothoraces: a case report
Safi Alqatari1* , Peter Riddell2, Sinead Harney3, Michael Henry2 and Grainne Murphy2
Abstract
Background: Clinically hypomyopathic dermatomyositis is a rare disease that is important to recognize, investigate
and treat early as it is associated with poor prognosis. In a proportion of patients, myositis specific antibodies could
be negative, but with high clinical suspicion, myositis associated antibodies should be ordered. Anti-MDA-5
antibodies was reported in literature to be associated with severe and rapidly progressive interstitial lung
disease, with few case reports of pneumothorax and/or pneumomediastinum.
Case presentation: A 49-year-old previously healthy lady, presented with a 6 week history of skin rash, photosensitivity,
mouth ulcers, fatiguability, arthralgia and myalgia. She denied subjective weakness, respiratory symptoms or dysphagia.
She had Raynaud’s phenomenon affecting her fingers only. Initial examination showed synovitis in her hands with skin
rash. Autoimmune screen was negative. She was started on hydroxychloroquine. 4 weeks later on follow-up,
she developed proximal muscle pain, dysphagia, dyspnea and dry cough. Examination showed mild proximal
muscle weakness and bi-basal crackles. She was admitted and extended myositis screen was sent. She had
mild anemia, lymphopenia and neutropenia, normal inflammatory markers, liver and renal panels.
Capillaroscopy showed pattern of systemic sclerosis. CT chest showed early ILD. Electromyography and MRI
showed features of mild myositis. PFT showed muscle weakness with low DLCO. She was given intravenous
steroid and Rituximab. As she continued to deteriorate, intravenous immunoglobulins and cyclophosphamide
were given. There was a brief clinical response that was short-lived with increasing oxygen dependency
necessitating transfer to the ICU. At this point, the extended myositis screen confirmed the presence of anti-
MDA-5 antibodies. She commenced plasmapharesis and required intubation. Unfortunately, she developed
multiple pneumothoraces, and was transferred urgently for ECMO. Subsequent immunosuppression included
rituximab and tacrolimus. There was progression of her ILD and recurrent pneumothoraces and pneumomediastinum.
Unfortunately, she passed away as a consequence of her disease.
Conclusion: This case highlights a number of considerations in approaching patients with inflammatory myositis,
particularly to pulmonary involvement. It is important to highlight the utility of extended myositis antibody testing in
predicting disease phenotypes and its impact on therapeutic decisions. From a management perspective, aggressive
immunosuppression should be considered with potential need of earlier utilization of ECMO.
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Background
Clinically hypomyopathic DM is a rare disease that is
important to recognize, investigate and treat early as it is
associated with poor prognosis. In a proportion of
patients, myositis specific antibodies are negative, but
with high clinical suspicion, myositis associated anti-
bodies should be ordered. Hypomyopathic dermatomyo-
sitis with positive anti-MDA-5 antibodies was reported
in literature to be associated with severe and rapidly pro-
gressive interstitial lung disease. There are a limited
number of case reports of associated pneumothorax
and/or pneumomediastinum largely in an Asian popula-
tion. We present a challenging case of rapidly progres-
sive interstitial lung disease (ILD) and pneumothorax/
pneumomediastinum in an Irish/Caucasian patient with
hypomyopathic MDA-5 positive dermatomyositis.
Case presentation
A 49-year-old lady was referred to the rheumatology ser-
vices with a 6-week history of an erythematous rash on
her face, fingers and feet which was painful, desquama-
tive and itchy. This was photosensitive in nature and
accompanied by painful mouth ulcers. More recently she
had noticed generalized myalgia, widespread joint pain
especially in her small joints, easy fatiguability and mal-
aise. She reported symptoms of Raynaud’s phenomenon
on exposure to cold two years prior. She denied respira-
tory symptoms, dysphagia or odynophagia. Examination
was remarkable for puffy fingers with polyarthritis
(MCPs, PIPs, DIPs, wrists and toes), peri-ungual
erythema and a desquamative rash. Power on initial
presentation was normal and there were no clinical find-
ings to suggest ILD. She was commenced on low dose
prednisolone and hydroxychloroquine and serological
testing was requested. A standard screen was negative
(RF, ACPA, ANA, ENA, ANCA). She had no family his-
tory of autoimmune disorders.
Over the ensuing 4 weeks she experienced a significant
deterioration. She developed new progressive proximal
muscle pain with no subjective weakness. She also re-
ported dysphagia to solids as well as dyspnea on minimal
exertion associated with a dry cough. Clinical examination
revealed a mild proximal myopathy and end inspiratory
bi-basal crackles. At that point, she was admitted for in-
vestigation and management including an extended myo-
sitis antibody panel. Results of her initial investigations are
summarized in Table 1.
Echocardiography was normal. Capillaroscopy showed
early and active pattern of systemic sclerosis. CT chest
showed early ILD in the form of non-specific interstitial
pneumonia (NSIP) (Fig. 1a, b). Electromyography
showed features of mild non-necrotic myopathy in the
quadriceps muscles. MRI of bilateral humeri and femora
showed features of myositis involving multiple muscle
groups (Fig. 1c, d). PFT showed restrictive pattern with
moderate DLCO reduction (DLCO 11.8 (predicted = 20),
FEV1 1.7 L (predicted = 2.02), FVC 2.1 (predicted = 2.4),
FEV//FVC = 80.95%).
She was commenced on methylprednisolone 500 mg
intravenously for 3 days and received Day 1 Rituximab
1 g, with a plan to retreat on Day 14. Unfortunately, she
developed a steroid-induced psychosis, necessitating a
reduction in subsequent prednisolone dosing. Over the
ensuing days she further deteriorated with radiological
progression of her ILD. In the context of progressive
dysphagia, she commenced IV Immunoglobulin and re-
ceived cyclophosphamide (15 mg/kg). There was a brief
clinical response following this combination but this was
short-lived with increasing oxygen dependency necessi-
tating transfer to the ICU for initial non-invasive ventila-
tion. At this point, the extended myositis screen
detected the presence of anti-MDA-5 antibodies con-
firming the diagnosis of hypomyopathic dermatomyo-
sitis. She commenced plasmapharesis for 5 days. She
required intubation due to respiratory fatigue and in-
creasing oxygen requirements. She developed multiple
pneumothoraces, and due to ventilatory difficulties was
transferred urgently for ECMO. Subsequent immuno-
suppression included day 14 rituximab and the addition
of tacrolimus. Despite aggressive immunosuppression
and prolonged ECMO therapy there was further pro-
gression of her interstitial lung disease, recurrent pneu-
mothoraces and pneumomediastinum. Unfortunately,
she passed away as a consequence of her disease.
Table 1 Results of blood tests
Test Result Test Result Test Result
WBCs 2.25/ L (4.4–11.3/L) Urea 2.4 mmol/L (2.8–8.4 mmol/L) Urinalysis Negative
Neutrophils 1.2/ L (1.4–6.6/L) Creatinine 54 micromol/L (49–90 micromol/L) ANA and ENA Negative
Lymphocytes 0.6/ L (0.9–3.2/L) ALT 48 U/L (0–34 U/L) DsDNA Negative
Hemoglobin 10.1 g/dl (11.7–15.9 g/dl) AST 78 U/L (6–42 U/L) C3 1.15 g/L (normal)
Platelets 420,000/L (140–440 X10*9/L LDH 1531 U/L (220–450 U/L) C4 0.30 g/L (normal)
ESR 7 mm (0–20 mm) CPK 208 U/L (40–180 U/L) RF and Anti-CCP Negative
CRP 2 mg/L (0–10 mg/L) Albumin 25 g/L (35–52 g/L) ANCA Negative
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Discussion and conclusion
Idiopathic inflammatory myopathies (IIMs) are a hetero-
geneous group of diseases [polymyositis (PM), dermato-
myositis (DM), inclusion body myositis (IBM), necrotizing
autoimmune myositis (NAIM)], characterized by myositis.
Other organs such as the skin in DM and the lungs, heart,
joints and gastrointestinal tract can be affected. Classifica-
tion of IIMs is important as different phenotypes and
serotypes are caused by different presentations, suggesting
the need for targeted therapies [1]. Autoantibody testing
has become crucial for the assessment of patients with
IIM (as described by Betteridge and McHugh) [2].
Auto-antibodies can be generally classified into
myositis-associated and myositis-specific antibodies. The
recognition of specific clinical phenotypes associated
with individual antibodies has had significant clinical
impact. Notable examples include the association of
antibodies directed at TIF-1gamma with malignancy.
Antisynthetase antibodies are strongly associated with
ILD, especially non-Jo-1 (anti-PL-7 and anti-PL-12)
where the association approaches 90–100% [3]. A rare
form of ILD with a very poor prognosis, is strongly asso-
ciated with CADM and the novel MDA- 5/anti-CADM-
140 auto-antibody. A combination of anti-Jo-1 and anti-
SSA/Ro antibodies also indicates severe pulmonary
involvement [3].
The strong association between ILD and myositis has
been recognized for many years and has led to the rou-
tine screening for ILD in individuals presenting with an
inflammatory myopathy. Clinically amyopathic or hypo-
myopathic dermatomyositis however may initially
present to a variety of specialties and ultimately this can
lead to diagnostic delay. These individuals may present
initially to respiratory services with symptoms and signs
of ILD. The advent of EMA testing has suggested that
particular antibodies segregate with propensity for ILD,
such as PL-7 and PL-12. Interestingly these individuals
who may present with imaging in keeping with estab-
lished fibrosis may respond to immunosuppression [3];
highlighting the importance of requesting extended anti-
body testing, even in the absence of circulating anti-
nuclear antibodies. In the case of MDA-5 antibodies in
particular, ILD can be rapidly progressive and, as in the
case discussed above, refractory to intensive immuno-
suppression, suggesting its valuable utility as a prognos-
tic indicator of disease severity.
In our case, it is probably the high pressure from ven-
tilatory support that caused the pneumothoraces but it
is important to highlight an interesting and perhaps less
recognized phenomenon, which is the potential for
pneumothoraces and pneumomediastinum. Both can
occur spontaneously as published in previous case
Fig. 1 Axial (a) and Coronal (b) CT (lung windows). Multifocal ground glass opacity progressing to consolidation in the dependent lungs. (d) Coronal
STIR Pelvis: T2 hyperintensity in gluteal, quadriceps and adductor musculature in keeping with myositis. (e) Axial T2FS Upper limbs: Further oedema
within trapezius, deltoid and rotator cuff musculature
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reports/series [4]. The aetiopathogeneis is poorly under-
stood but multiple theories have been proposed. These
include the presence of raised intra-alveolar pressure
which leads to rupture of previously damaged alveoli, or
rupture of subpleural cyst(s) that developed from co-
existing interstitial fibrosis. Another factor could be the
presence of an underlying lung vasculitis, as DM is asso-
ciated with inflammation of small blood vessels [4].
Many patients with rapidly progressive ILD and amyo-
pathic myositis needed a combination of multiple immu-
nosuppressives and steroids for a prolonged period (up to
twelve months in some reports) highlighting the aggres-
sive nature of ILD in this cohort.
Given the rarity of individuals with myositis associated
antibodies, trials aiming to target a particular therapy by
antibody type do not exist. Existing reports suggest that
initial high dose steroids are the most common initial
therapy used and perhaps the most effective medication
in controlling acute disease. They are used in conjunc-
tion with a variety of additional immunosuppressives in-
cluding cyclophosphamide, mycophenolate mofetil,
ciclosporin and tacrolimus and biologic medication,
commonly rituximab. Of note, rituximab offers dual
benefit in treating accompanying myopathy and is also
gaining increasing attention in treating ILD in the con-
text of connective tissue disorders. Some studies sug-
gested that the addition of tacrolimus improved the
disease free survival of PM/DM as will as ILD. However,
the number of patients involved in those studies were
small [5].
Finally, the impact of ECMO therapy merits discussion
and particularly its role in reducing the risk of pneumo-
thorax in this setting. In the case of rapidly progressive
ILD associated with CADM, the use of ECMO should
be considered early in the disease process, especially in
potentially reversible conditions to avoid the need for
mechanical ventilation [6].
In conclusion, this case highlights a number of critical
considerations in approaching patients with inflamma-
tory myositis, particularly in relation to associated pul-
monary involvement. While ILD has long been
recognized as a potential complication of myositis, the
potential for ILD to be the prominent feature of presen-
tation is now well described particularly in a subgroup
of patients with little clinical evidence of myopathy. We
wish to highlight the importance of clinical surveillance
for the development of myopathy in individuals with
amyopathic or hypomyopathic dermatomyositis; the util-
ity of extended myositis antibody testing in predicting
disease phenotypes and the potential impact on subse-
quent management in this cohort. Of particular signifi-
cance, this case emphasized the importance of early
consideration of ECMO to decrease the risk of pneumo-
thorax/ mediastinum.
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